The French in vitro diagnostics company slightly lowered its full-year revenue guidance to adjust for a late respiratory infection season.

The next-generation sequencing-based test is designed to capture all clinically relevant cystic fibrosis mutations in a single assay.

As a result of the firm's financial results, Castle Bio raised its full-year 2025 revenue guidance to between $327 and $335 million from a range of $310 to $320 million.